Clinical trial · Interventional
Effect of Magnesium Sulphate on Coagulation
Effect of Magnesium Sulphate on Postoperative Coagulation as Measured by Thromboelastography
NCT01032213CI-TRIAL-00011878completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Arterial and venous thrombotic events are the clinical manifestation of postoperative hypercoagulability. Altered serum magnesium may play a role in the balance of coagulation. In this study, the investigators investigated the effect of magnesium sulphate on the postoperative coagulation change in total intravenous anesthesia (TIVA).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myoma | Myoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnesium Sulfate | Drug | — | UNRESOLVED |
| normal saline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- group C
- description
- control group
- interventionNames
- Drug: normal saline
- type
- EXPERIMENTAL
- label
- group M
- description
- magnesium group
- interventionNames
- Drug: Magnesium Sulfate
Primary outcomes (1)
- measure
- thromboelastography (TEG) analysis
- timeFrame
- twice
- description
- 1. 10 minutes before the induction of anesthesia 2. 10 minutes after the recovery from the anesthesia
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * ASA Ⅰ-Ⅱ patients undergoing pelviscopic gynecologic operation under general anesthesia. Exclusion Criteria: * Pregnancy * Previous known hematologic disorder * Recent medication interfering with hemostasis * Severe anemia * Liver disease * Cardiovascular or respiratory disease
References
Publications (0)
Data not yet available
No reference posted for this study.